A retrospective mRNA-based analysis for ERBB2, using qRT-PCR for baseline tumour samples from the chemotherapy-free arm, showed 23.4% and 10.9% pCR rates in ERBB2-high and ERBB2-low groups, respectively [38]. Here, ERBB2 is linked to neoplasm.